Trial Profile
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age With Attention Deficit Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Dasotraline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 30 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Jul 2014 New trial record
- 23 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.